---
title: "Zymeworks Earns Buy Rating as Non-Dilutive Theravance Deal and Long-Duration YUPELRI Cash Flows Drive Price Target Up to $37"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291260988.md"
description: "Citi analyst Yigal Nochomovitz maintained a Buy rating on Zymeworks with a $37 price target, citing the non-dilutive Theravance deal and long-duration YUPELRI cash flows. Wells Fargo also issued a Buy rating with a $37 target. The positive outlook is driven by disciplined execution, attractive royalty aggregation strategy, and potential milestone payments."
datetime: "2026-06-30T09:55:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291260988.md)
  - [en](https://longbridge.com/en/news/291260988.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291260988.md)
generator: "portal-rs"
---

# Zymeworks Earns Buy Rating as Non-Dilutive Theravance Deal and Long-Duration YUPELRI Cash Flows Drive Price Target Up to $37

Citi analyst Yigal Nochomovitz maintained a Buy rating on Zymeworks yesterday and set a price target of $37.00.

### End of Quarter Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

Yigal Nochomovitz has given his Buy rating due to a combination of factors tied to Zymeworks’ disciplined execution and attractive cash-flow profile. He views the Theravance Biopharma deal as a smart first step in the company’s royalty aggregation strategy, with limited upfront risk, meaningful exposure to YUPELRI economics, and incremental upside from ex-U.S. royalties and pipeline options.

Separately, he highlights that the financing is structured to be non-dilutive and largely self-funded by YUPELRI profit-sharing, supporting a mid-teens internal rate of return with visible, long-duration cash flows through 2039. Combined with potential milestone payments from Viatris and zani’s upcoming PDUFA event, these factors underpin his raised price target of $37 and reinforce his positive stance on the stock. 

In another report released yesterday, Wells Fargo also maintained a Buy rating on the stock with a $37.00 price target.

### Related Stocks

- [ZYME.US](https://longbridge.com/en/quote/ZYME.US.md)
- [TBPH.US](https://longbridge.com/en/quote/TBPH.US.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [VTRS.US](https://longbridge.com/en/quote/VTRS.US.md)
- [WFC.US](https://longbridge.com/en/quote/WFC.US.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)
- [WFC-D.US](https://longbridge.com/en/quote/WFC-D.US.md)
- [WFC-L.US](https://longbridge.com/en/quote/WFC-L.US.md)
- [WFC-Y.US](https://longbridge.com/en/quote/WFC-Y.US.md)
- [WFC-C.US](https://longbridge.com/en/quote/WFC-C.US.md)
- [WFC-Z.US](https://longbridge.com/en/quote/WFC-Z.US.md)
- [WFC-A.US](https://longbridge.com/en/quote/WFC-A.US.md)

## Related News & Research

- [How Zymeworks’ Bigger Loss, Buyback and Milestones Pivot At Zymeworks (ZYME) Has Changed Its Investment Story](https://longbridge.com/en/news/296173401.md)
- [Zymeworks (ZYME) Back In Focus After Q2 Loss, Buyback, And Pipeline Events Raised Valuation Questions](https://longbridge.com/en/news/296030517.md)
- [Wedge Capital Management L L P NC Buys Shares of 128,845 Theravance Biopharma, Inc. $TBPH](https://longbridge.com/en/news/295997292.md)
- [Cantor Fitzgerald Sticks to Its Buy Rating for DeFi Development Corporation (DFDV)](https://longbridge.com/en/news/296108554.md)
- [Jefferies Sticks to Its Buy Rating for Covista (CVSA)](https://longbridge.com/en/news/296118987.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**